Medicare Going Forward – The Impacts of Insurer Consolidations and Targeted Drugs

With the Medicare Hospital Insurance Fund projected to be depleted by 2030, there is so me solace in the expectations that Medicare Part B and Part D will remain solvent for a much longer period. That’s good news, but there are developing trends that could cause these projections to miss the part substantially. The trend toward consolidation among major drug companies, for example, may result in limitations on competition and a resulting ramp-up in drug prices. At the same time, next-generation drugs for Hepatitis C, cancer treatment, and cholesterol drugs are rising in cost at an alarming pace. In a post on www.fool.com, Sean Williams presents insights into this concern. Read the article here…

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.